Downtrend on the daily chart: below its 50-day average · SuperTrend down since Oct 9 · below the Ichimoku cloud · RSI 33 · MACD below its signal
None of the 29 investors followed here reported a position in ELOX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ELOX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Feb 26, 2026 | Aggarwal SumitChief Executive Officer | Conversion of Exercise of derivative security at price 0.00 - 0.15 per share. | 472.8K | $39.16K |
| Jan 22, 2026 | Rubin Steven DanielDirector | — | 1.9K | — |
| Jan 22, 2026 | Walts Alan Edmund Ph.D.Director | — | 1.9K | — |
| Sep 18, 2025 | Aggarwal SumitChief Executive Officer | — | 1.00M | — |
| Jan 23, 2025 | Rubin Steven DanielDirector | — | 3.8K | — |
| Jan 23, 2025 | Aggarwal SumitDirector | — | 30K | — |
| Jan 23, 2025 | Walts Alan Edmund Ph.D.Director | — | 3.8K | — |
| Jan 23, 2025 | Androski Lindsay J.D.Director | — | 3.8K | — |
| Oct 15, 2024 | Rubin Steven DanielDirector | — | 12K | — |
| Oct 15, 2024 | Aggarwal SumitChief Executive Officer | — | 165K | — |
| Oct 15, 2024 | Walts Alan Edmund Ph.D.Director | — | 12K | — |
| Oct 15, 2024 | Androski Lindsay J.D.Director | — | 12K | — |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Buy / hold / sell counts